Chiesi, the international research-focused biopharmaceutical and healthcare group, has announced that its phase III clinical safety trial for the development of an innovative carbon minimal inhaler platform is underway.1 The carbon minimal inhaler will replace the current hydrofluorocarbon propellant (HFC 134a) ...

Related Keywords

United Kingdom , London , City Of , Manchester , Ireland , Ralph Blom , Chiesi Group , Global Initiative For Chronic Obstructive Pulmonary Disease , Global Initiative For Asthma , Net Zero , General Manager , Chiesi United Kingdom , Subjects With , Two Propellants , Adults With Mild , Lung United , Chronic Obstructive Pulmonary Disease , Clin Risk , Chronic Obstructive Pulmonary ,